All In Biotech

Drug Trial Radar · NCT00379821

Chloroquine Alone or in Combination for Malaria in Children in Malawi

A Longitudinal Study of Chloroquine as Monotherapy or in Combination With Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria in Children in Blantyre, Malawi

Last checked: Nov 20, 2026Latest source record: Aug 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 640 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

640

Actual

Start

Feb 2007

Primary completion

Aug 2009

Study completion Sep 2012

Sponsor

Sponsor type
NIH
First posted
Sep 25, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 months, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Malaria is a sickness caused by a germ that can get into a person's body when a mosquito bites them. It can cause fever, headache, body aches and weakness. It can even cause death, especially in children. When malaria is treated with the appropriate medicine(s), it can be cured completely. The purpose of this study is to find out if it is better to use chloroquine alone or in combination with another drug to most effectively treat malaria. About 640 children with malaria, aged 6 months to 5 years of age, from the Blantyre Malaria Project Research Clinic at the Ndirande Health Center in Malawi will be in the study. They will be treated with either chloroquine alone or a combination of chloroquine plus another medication (azithromycin or artesunate or atovaquone-proguanil) every time they get malaria for a year. Blood samples will be collected and tested at least every 4 weeks. Participants will be involved in the study for 1 year.

Conditions

  • Plasmodium Falciparum Infection

Interventions

  • Atovaquone-proguanilDrug

    Atovaquone-proguanil: once a day for 3 days, Pediatric tablet: 62.5 mg/25 mg, Full strength tablet: 250 mg/100 mg

  • ArtesunateDrug

    Artesunate: 4mg/kg once a day for 3 days, 50 mg tablet

  • AzithromycinDrug

    Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension

  • ChloroquineDrug

    Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Clinical Malaria Episodes Per Year of Follow-upTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Blantyre Malaria Project - Ndirande Health Centre

    Blantyre, Blantyre, Malawi

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.